Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Acorda Therapeutics, Inc is a biotechnology business based in the US. Acorda Therapeutics shares (ACOR) are listed on the NASDAQ and all prices are listed in US Dollars. Acorda Therapeutics employs 344 staff and has a trailing 12-month revenue of around USD$165.3 million.
Since the stock market crash in March caused by coronavirus, Acorda Therapeutics's share price has had significant negative movement.
Its last market close was USD$0.69, which is 54.61% down on its pre-crash value of USD$1.52 and 1.46% down on the lowest point reached during the March crash when the shares fell as low as USD$0.7001.
If you had bought USD$1,000 worth of Acorda Therapeutics shares at the start of February 2020, those shares would have been worth USD$430.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$339.90.
|Latest market close||USD$0.69|
|52-week range||USD$0.42 - USD$2.77|
|50-day moving average||USD$0.8117|
|200-day moving average||USD$0.7181|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.022|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||-6.76%|
|1 month (2020-10-30)||-20.69%|
|3 months (2020-09-01)||30.19%|
|6 months (2020-06-01)||-10.39%|
|1 year (2019-11-29)||-56.88%|
|2 years (2018-11-30)||-96.62%|
|3 years (2017-12-01)||-96.68%|
|5 years (2015-12-01)||-98.18%|
Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acorda Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Acorda Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$165.3 million|
|Gross profit TTM||USD$157.6 million|
|Return on assets TTM||-6.37%|
|Return on equity TTM||16.51%|
|Market capitalisation||USD$34.2 million|
TTM: trailing 12 months
There are currently 7.2 million Acorda Therapeutics shares held short by investors – that's known as Acorda Therapeutics's "short interest". This figure is 25.1% down from 9.7 million last month.
There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.
Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 10.6 million). Acorda Therapeutics's SIR currently stands at 0.68. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 680 shares are currently held short.
However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1282% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 128 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.
Find out more about how you can short Acorda Therapeutics stock.
We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $0.42 up to $2.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.9357. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.